Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-12. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
At least three isotopes of iodine are important. 129I, 131I (radioiodine) and 132I. Open air nuclear testing and the Chernobyl disaster both released iodine-131. The short-lived isotopes of iodine are particularly harmful because the thyroid collects and concentrates iodide – radioactive as well as stable. Absorption of radioiodine can lead to acute, chronic, and delayed effects. Acute effects from high doses include thyroiditis, while chronic and delayed effects include hypothyroidism, thyroid nodules, and thyroid cancer. It has been shown that the active iodine released from Chernobyl and Mayak has resulted in an increase in the incidence of thyroid cancer in the former Soviet Union. One measure which protects against the risk from radio-iodine is taking a dose of potassium iodide (KI) before exposure to radioiodine. The non-radioactive iodide "saturates" the thyroid, causing less of the radioiodine to be stored in the body. Administering potassium iodide reduces the effects of radio-iodine by 99% and is a prudent, inexpensive supplement to fallout shelters. A low-cost alternative to commercially available iodine pills is a saturated solution of potassium iodide. Long-term storage of KI is normally in the form of reagent-grade crystals. The administration of known goitrogen substances can also be used as a prophylaxis in reducing the bio-uptake of iodine, (whether it be the nutritional non-radioactive iodine-127 or radioactive iodine, radioiodine - most commonly iodine-131, as the body cannot discern between different iodine isotopes).
== Medical use == Lixisenatide is used as adjunct to diet and exercise to treat type 2 diabetes. In the European Union, its use is limited to complementing insulin therapy. As of 2017 it is unclear if they affect a person's risk of death. It is provided in an autoinjector containing fourteen doses and is injected subcutaneously. Lixisenatide should not be used for people who have problems with stomach emptying. Lixisenatide delays emptying of the stomach, which may change how quickly other drugs that are taken by mouth take effect.
Carbamic acid, which might also be called aminoformic acid or aminocarboxylic acid, is the chemical compound with the formula H2NCOOH. It can be obtained by the reaction of ammonia NH3 and carbon dioxide CO2 at very low temperatures, which also yields ammonium carbamate [NH4]+[NH2CO2]−. The compound is stable only up to about 250 K (−23 °C); at higher temperatures it decomposes into those two gases. The solid apparently consists of dimers, with the two molecules connected by hydrogen bonds between the two carboxyl groups –COOH. Carbamic acid could be seen as both an amine and carboxylic acid, and therefore an amino acid; however, the attachment of the carboxyl group –COOH directly to the nitrogen atom (without any intermediate carbon chain) makes it behave very differently from the amino acids with intermediate carbon chain. (Glycine NH2CH2COOH is generally considered to be the simplest amino acid.) The hydroxyl group –OH attached to the carbon also excludes it from the amide class. The term "carbamic acid" is also used generically for any compounds of the form RR′NCOOH, where R and R′ are organic groups or hydrogen. Deprotonation of a carbamic acid yields a carbamate anion RR′NCOO−, the salts of which can be relatively stable. Carbamate is also a term used for esters of carbamic acids, such as methyl carbamate H2N−C(=O)−OCH3. The carbamoyl functional group RR′N–C(=O)– (often denoted by Cbm) is the carbamic acid molecule minus the OH part of the carboxyl.
== Applications == Linear elasticity is used widely in the design and analysis of structures such as beams, plates and shells, and sandwich composites. This theory is also the basis of much of fracture mechanics. Hyperelasticity is primarily used to determine the response of elastomer-based objects such as gaskets and of biological materials such as soft tissues and cell membranes.
== Notable people == Túpac Amaru II, revolutionary Angélica Mendoza de Ascarza, Peruvian human rights activist Kimberly Barzola, American community organizer and artist Benjamin Bratt, American actor Manco Cápac, Sapa Inca Luzmila Carpio, Bolivian musician Andrónico Rodríguez, Bolivian trade unionist and politician Martín Chambi, Peruvian photographer Renata Flores Rivera, Peruvian musician Oswaldo Guayasamín, Ecuadorian painter Ollanta Humala, former president of Peru Antauro Humala, Peruvian ethnocacerist Josh Keaton, American actor Q'orianka Kilcher, American actress Nancy Iza Moreno, Kichwa leader Leonidas Iza, Ecuadorian activist and Indigenous leader Delfín Quishpe, Ecuadorian musician and politician Tarcila Rivera Zea, Peruvian activist Izkia Siches, Chilean physician and politician Magaly Solier, Peruvian actress and musician Diego Quispe Tito, painter Francisco Tito Yupanqui, sculptor Alejandro Toledo, former president of Peru Edison Flores, Peruvian footballer Renato Tapia, Peruvian footballer Tania Pariona Tarqui, Peruvian politician
Sources: en.wikipedia.org
== Causes == It can occur in patients with severely compromised intestinal function, those undergoing total parenteral nutrition, those who have had gastrointestinal bypass surgery, and also in persons of advanced age (i.e., over 90). People dependent on food grown from selenium-deficient soil may be at risk for deficiency. Increased risk for developing various diseases has also been noted, even when certain individuals lack optimal amounts of selenium, but not enough to be classified as deficient. For some time now, it has been reported in the medical literature that a pattern of side effects possibly associated with cholesterol-lowering drugs (e.g., statins) may resemble the pathology of selenium deficiency.
A Broadway production named Shining City was Platt's Broadway debut in 2006. The play was set in Dublin, and Platt's role was the tortured protagonist, John. Shining City's director said, "There is one word to describe Oliver. It's 'humanity.' He's got that everyman quality. He's a contradictory human being with flaws and strengths. And he's loveable. He can simultaneously make you laugh and break your heart. Oliver has brought to the role of John what I expected and more: tremendous inventiveness and sensitivity." Platt visited Dublin to prepare for the role and ensure his performance was authentic. He was nominated for a Tony Award for "Best Performance by a Leading Actor in a Play". In 2007, Platt played the part of Yankees owner George Steinbrenner in the ESPN mini-series The Bronx Is Burning. Platt signed onto the project after John Turturro was confirmed as Billy Martin, because "This thing lives or dies by that portrayal ... I think it's great casting. God knows he has the intensity." Platt starred in the pilot episode of The Thick of It, a remake of the British show of the same name in 2007. The series was not picked up by ABC. Platt starred as Nathan Detroit, alongside Lauren Graham as Miss Adelaide, in the Broadway revival of Guys and Dolls which began performances at the Nederlander Theatre on February 3, 2009, and officially opened on March 1, 2009. The production closed on June 14, 2009, after 113 performances. Platt starred as White House Chief of Staff Carl Anheuser in Roland Emmerich's 2012, a disaster film released November 13, 2009.
=== Pharmacokinetics === Following single or multiple intravenous infusions, the majority of drug elimination occurs within 24 hours of intravenous administration. The elimination half-life of golodirsen, in parity with eteplirsen was 3 to 6 hours.
==== Left 4 Dead branch ==== The Left 4 Dead branch is an overhaul of many aspects of the Source engine through the development of the Left 4 Dead series. Multiprocessor support was further expanded, allowing for features like split screen multiplayer, additional post-processing effects, event scripting with Squirrel, and the highly-dynamic AI Director. The menu interface was re-implemented with a new layout designed to be more console-oriented. This branch later fueled the releases of Alien Swarm and Portal 2, the former released with source code outlining many of the changes made since the branch began. Portal 2, in addition, served as the result of Valve taking the problem of porting to PlayStation 3 in-house, and in combination with Steamworks integration creating what they called "the best console version of the game".
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.